Our former study not only provided a functional explanation for the reportedly impaired efficacy of rituximab to induce NK cell reactivity in CLL, but also introduced BAFF neutralization as means to increase the efficacy of CD20 antibody treatment in this disease [24,57]. This evidence concerns the gene TNFSF13B and B-cell chronic lymphocytic leukemia.